JP2021515793A5 - - Google Patents

Info

Publication number
JP2021515793A5
JP2021515793A5 JP2020548783A JP2020548783A JP2021515793A5 JP 2021515793 A5 JP2021515793 A5 JP 2021515793A5 JP 2020548783 A JP2020548783 A JP 2020548783A JP 2020548783 A JP2020548783 A JP 2020548783A JP 2021515793 A5 JP2021515793 A5 JP 2021515793A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
her2
conjugate according
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020548783A
Other languages
English (en)
Japanese (ja)
Other versions
JP7547205B2 (ja
JP2021515793A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/050303 external-priority patent/WO2019173911A1/en
Publication of JP2021515793A publication Critical patent/JP2021515793A/ja
Publication of JP2021515793A5 publication Critical patent/JP2021515793A5/ja
Application granted granted Critical
Publication of JP7547205B2 publication Critical patent/JP7547205B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020548783A 2018-03-13 2019-03-12 抗her2バイパラトピック抗体-薬物コンジュゲート及び使用方法 Active JP7547205B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862642483P 2018-03-13 2018-03-13
US62/642,483 2018-03-13
US201862658477P 2018-04-16 2018-04-16
US62/658,477 2018-04-16
US201862743884P 2018-10-10 2018-10-10
US62/743,884 2018-10-10
PCT/CA2019/050303 WO2019173911A1 (en) 2018-03-13 2019-03-12 Anti-her2 biparatopic antibody-drug conjugates and methods of use

Publications (3)

Publication Number Publication Date
JP2021515793A JP2021515793A (ja) 2021-06-24
JP2021515793A5 true JP2021515793A5 (cg-RX-API-DMAC7.html) 2022-03-18
JP7547205B2 JP7547205B2 (ja) 2024-09-09

Family

ID=67908692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020548783A Active JP7547205B2 (ja) 2018-03-13 2019-03-12 抗her2バイパラトピック抗体-薬物コンジュゲート及び使用方法

Country Status (22)

Country Link
US (3) US20210260210A1 (cg-RX-API-DMAC7.html)
EP (2) EP4253421A3 (cg-RX-API-DMAC7.html)
JP (1) JP7547205B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200131840A (cg-RX-API-DMAC7.html)
CN (1) CN112020519A (cg-RX-API-DMAC7.html)
AU (1) AU2019235634A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020018618A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093477A1 (cg-RX-API-DMAC7.html)
DK (1) DK3765525T5 (cg-RX-API-DMAC7.html)
ES (1) ES2958933T3 (cg-RX-API-DMAC7.html)
FI (1) FI3765525T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231280T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063489T2 (cg-RX-API-DMAC7.html)
IL (1) IL277049B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020009469A (cg-RX-API-DMAC7.html)
NZ (1) NZ768561A (cg-RX-API-DMAC7.html)
PL (1) PL3765525T3 (cg-RX-API-DMAC7.html)
PT (1) PT3765525T (cg-RX-API-DMAC7.html)
RS (1) RS64690B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008770QA (cg-RX-API-DMAC7.html)
TW (1) TWI822740B (cg-RX-API-DMAC7.html)
WO (1) WO2019173911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3223848T3 (fi) * 2014-11-27 2025-02-28 Zymeworks Bc Inc Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een
CA2984458A1 (en) 2015-05-13 2016-11-17 Zymeworks Inc. Antigen-binding constructs targeting her2
AU2019235634A1 (en) 2018-03-13 2020-10-22 Zymeworks Bc Inc. Anti-HER2 biparatopic antibody-drug conjugates and methods of use
CN115811991A (zh) * 2019-08-14 2023-03-17 加利福尼亚大学董事会 用于癌症免疫治疗的智能肽和可转化纳米颗粒
EP4130033A4 (en) * 2020-03-30 2024-08-07 National Institutes of Biomedical Innovation, Health and Nutrition EPITOPE REGION BYPASSING BIPARATOPIC ANTIBODY AND PRODUCTION METHOD THEREOF
JP2024504454A (ja) * 2021-01-29 2024-01-31 上▲海▼翰森生物医▲薬▼科技有限公司 抗体-薬物コンジュゲート及びその医学的使用
JP2024519523A (ja) * 2021-04-26 2024-05-15 スアンズ バイオファーマシューティカル カンパニー,リミテッド 二重特異性抗体薬物コンジュゲート
JP2024525624A (ja) * 2021-07-05 2024-07-12 チャンスー アルファマブ バイオファーマシューティカルズ カンパニー,リミテッド 抗体薬物コンジュゲート及びその使用
WO2023141714A1 (en) * 2022-01-26 2023-08-03 Zymeworks Bc Inc. Methods of using anti-her2 biparatopic antibody-drug conjugates in the treatment of cancer
CN116003609B (zh) * 2022-07-04 2026-03-06 倍而达药业(苏州)有限公司 erb-B2双特异性抗体、药物组合物及其用途
WO2024230301A1 (zh) * 2023-05-09 2024-11-14 诺灵生物医药科技(北京)有限公司 一种抗体偶联药物及其用途
WO2025162287A1 (zh) * 2024-01-29 2025-08-07 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗肠癌的用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
JP2010510500A (ja) * 2006-11-24 2010-04-02 ジェミナ アセット マネージメント (6) ピーティーワイ リミテッド 電源監視システム
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
CA2784610C (en) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
TW201141519A (en) * 2010-03-04 2011-12-01 Symphogen As Anti-HER2 antibodies and compositions
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
US20140170148A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
BR112013027173B1 (pt) * 2011-04-29 2019-08-06 Becton, Dickinson And Company Sistema de classificador de célula, método para calibrar um sistema de classificador de célula, e sistema de controle de retardo de carga para um citômetro de fluxo
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
BR112014031613A2 (pt) * 2012-06-19 2017-07-25 Polytherics Ltd processo para preparação de conjugados de anticorpos e conjugados de anticorpos
IN2015DN01115A (cg-RX-API-DMAC7.html) 2012-07-13 2015-06-26 Zymeworks Inc
EP2906591A1 (en) 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
TW201519904A (zh) 2013-03-15 2015-06-01 Abbvie Inc 抗體藥物結合物(adc)之純化
US10239951B2 (en) * 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
EP3004174B1 (en) 2013-05-31 2019-04-17 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
US9877080B2 (en) * 2013-09-27 2018-01-23 Samsung Electronics Co., Ltd. Display apparatus and method for controlling thereof
PT3480215T (pt) 2013-11-19 2021-07-05 Remegen Ltd Anticorpo anti-her2 e seu conjugado
LT3074424T (lt) * 2013-11-27 2025-05-26 Zymeworks Bc Inc. Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
JP6510532B2 (ja) 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性her2抗体及び使用方法
KR102384740B1 (ko) * 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
WO2015104373A2 (en) 2014-01-10 2015-07-16 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in treatment of endometrial cancer
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
DK3151865T3 (da) 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
ES2905569T3 (es) * 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
FI3223848T3 (fi) * 2014-11-27 2025-02-28 Zymeworks Bc Inc Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een
CA2984458A1 (en) * 2015-05-13 2016-11-17 Zymeworks Inc. Antigen-binding constructs targeting her2
EP3383909B1 (en) 2015-11-30 2020-06-17 AbbVie Inc. Anti-human lrrc15 antibody drug conjugates and methods for their use
WO2017185177A1 (en) 2016-04-25 2017-11-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
US10377833B2 (en) 2016-07-22 2019-08-13 Beijing Mabworks Biotech Co., Ltd. Bispecific anti-HER2 antibody
AU2019235634A1 (en) 2018-03-13 2020-10-22 Zymeworks Bc Inc. Anti-HER2 biparatopic antibody-drug conjugates and methods of use

Similar Documents

Publication Publication Date Title
FI3765525T3 (fi) Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä
JP2023537051A5 (cg-RX-API-DMAC7.html)
JP2025131777A5 (cg-RX-API-DMAC7.html)
JP2019533719A5 (cg-RX-API-DMAC7.html)
JP2021512630A5 (cg-RX-API-DMAC7.html)
JP2023123726A5 (cg-RX-API-DMAC7.html)
JP2022506072A5 (cg-RX-API-DMAC7.html)
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
JP2022535924A5 (cg-RX-API-DMAC7.html)
JP2020508997A5 (cg-RX-API-DMAC7.html)
JP2019502712A5 (cg-RX-API-DMAC7.html)
JP2023516004A5 (cg-RX-API-DMAC7.html)
JP2021533169A5 (cg-RX-API-DMAC7.html)
JP2008526234A5 (cg-RX-API-DMAC7.html)
JP2024501539A5 (cg-RX-API-DMAC7.html)
JP2024515536A5 (cg-RX-API-DMAC7.html)
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2021533159A5 (cg-RX-API-DMAC7.html)
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
JP2024504390A5 (cg-RX-API-DMAC7.html)
JP2023511376A5 (cg-RX-API-DMAC7.html)
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2020502233A5 (cg-RX-API-DMAC7.html)
JP2021512613A5 (cg-RX-API-DMAC7.html)